APPLICATIONS PUBLISHED 5 JANUARY 2005
Published: 3-Jan-2006
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Urea compsns
Yu, Ruey; Van Scott, Eugene 1492486*
Mitotic kinesin inhibitors
Merck 1492487*
Cross-linked cosmetic or pharmaceutical phospholipid-containing gels and emulsions based on ethylene oxide-containing or propylene oxide-containing emulsifiers
Beiersdorf 1492488*
Waterproof cosmetic and dermatological sun-protecting formulations containing polyoxyethylene-polydodecyl glycol-block polymers
Beiersdorf 1498489*
Cosmetic or pharmaceutical low-viscosity (atomisable) O/W emulsions containing phospholipids
Beiersdorf 1492490*
Cross-linked-oil-droplet-based cosmetic or pharmaceutical emulsions
Beiersdorf 1492491*
Formoterol and mometasone aerosol formulations
3M Innovation Properties Company 1492499*
Novel polymorphs and pseudopolymorphs of risedronate sodium
Teva Pharmaceutical Industries 1492502*
Stabilised natural cannabinoid formulation
Solvay Pharmaceuticals 1492503*
Taste-masked compsns of erythromycin A and derivatives thereof
Ranbaxy Laboratories 1492504*
Pharmaceutical preparation containing oxycodone and naloxone
Euro-Celtique 1492505*
Matrix for sustained, invariant and independent release of active compounds
Euro-Celtique 1492506*
Clarithromycin formulations having improved bioavailability
Ranbaxy Laboratories 1492507*
Controlled release dosage forms
Teva Pharmaceutical Industries 1492508*
Dosage form providing time-varyine patterns of drug delivery
ALZA Corp 1492509*
Low-dose liquid entacavir formulations and use
Bristol-Myers Squibb 1492510*
Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
Flamel Technologies 1492511*
Method for systemic drug delivery through the nail
Novartis 1492512*
HFA-suspension formulations containing an anticholinergic
Boegringer Ingelheim Laboratories 1492513*
A method for treating carrier particles and its use
Lab Pharma Oy 1492514
Pharmaceutical compsn comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
Jencap Research 1492515*
Use of MOB-5 in pain
Novartis 1492516*
Hot melt TTS for administering rotigotine
Schwartz Pharma 1492517*
Tuberculosis treatment using pleuromutilin derivatives
Sandoz 1492518*
Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
Dynogen Pharmaceuticals 1492519*
Pharmaceutical compsns
Novartis 1492520*
Combined use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratosperma
Sigma-Tau Industrie Farmaceutiche Riunite 1492521*
Ansamycin formulations and methods for producing and using same
Conforma Therapeutics Corp 1492522*
Method for identification of tumour targeting enzymes
Chugai Seiyaku KK 1492523*
Vitamin combinayion for providing protection during the chemotherapy and/or radiotherapy of malignant tumours
Haemato-Basics 1492524*
Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphophate concentration dependent on intracellular signal cascades
Probiodrug 1492525*
Improved prodrugs of CC-1065 analogues
Immunogen 1492526*
Process for preparing a finelty self-emulsifiable pharmaceutical compsn
Pharmacia 1492527*
Antidiabetic agents
Warner-Lambert 1492528*
Oral administration of epothilones
Bristol-Myers Squibb 1492529*
Thiazol-2-yl-imine compounds as PDE-7 inhibitors
Warner-Lambert 1492530*
Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
Flamel Technologies 1492531*
Combinations of epinastine, belladonna and pseudoephidrine as new pharmaceutical formulations
Boehringer Ingelheim International 1492532*
N-substituted pyridinone and pyramidinone derivatives for use as PLA2 inhibitors in the treatment of atherosclerosis
Glaxo Group 1492533*
Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
TopoTarget UK 1492534*
Anhydrous crystalline forms I and II of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl) 4-oxo-1,4-dihydroquinoline-3-carboxylic acid (Gatifloxacin)
Dr Reddy's Laboratories 1492535*
4-(N-phenylamino) quinazolines/quinazolinones as tyrosine kinase inhibitors
Boehringer Ingelgheim Pharma 1492536*
Morpholine derivatives with a substituted acetamide group in the 2-position for use as CCR-3 antagonists for the treatment of inflammatory diseases
Glaxo Group 1492537*
Meloxicam suppositories containing eg polyethyleneglycol
Boegringer Ingelheim 1492538*
Statin therapy for enhancing cognitive maintenance
Janssen Pharmaceutica 1492539*
The use of devazepide as analgesic agent
MIL Laboratories 1492540*
Pharmaceutical compsns comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
The University of Edinburgh 1492541*
Hormone replacement therapy
Wyeth 1492542*
Drugs for arthritis treatment
Nicox 1492543*
Pharmaceutical compsns containing water-soluble prodrugs of propofol and methods of administering same
Guilford Pharmaceuticals 1492544*
Agents for treating flaviviridae infections
Viromics 1492545*
Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system
Trommsdorff 1492547*
Low-dose potassium supplementation for the prevention and treatment of hypertension
BTG International 1482547*
Compsn for the topical treatment of vulvovaginitis and mycoses
Bergamon 1492548*
Compsns and methods for augmenting kidney function
Kibow Biotech 1492549*
Willow extract
Dr. Willmar Schwabe GmbH 1492550*
Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
Natural Disinfectant Technologies 1492551*
Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (FPRL1)
Bayer 1492552*
CG8327, CG10823, CG18418, CG15862, CG3768, CG11447 and CG16750 homologous proteins involved in the regulation of energy homeostasis
DeveloGen Aktiengesellschaft fuer entwicklungsbiologische Forschung 1492553*
Spherical protein particles and methods of making and using them
Albus Biologics 1492554*
Compsns and methods for modulation of effects of phagocyte and lymphoid cell population
Utku, Nalan 1492555*
Use of long pentraxin PTX3 for the treatment of fgf-8 mediated tumour diseases
SIGMA-TAU Industrie Farmaceutiche Riunite 1492556*
XCRF polynucleotides and polypeptides and uses thereof
Serono Genetics Institute 1492557*
Novel secreted proteins and their uses
Eli Lilly 1492558*
Truncated 24KDA basic fibroblast growth factor
Levin, Eugene 1492559*
Use of interleukin-19 to treat cervical cancer
ZymoGenetics 1492560*
Methods for treating mammary gland disorders
Allergan 1492561*
Virus-like particles of human papillomavirus
GlaxoSmithKline Biologicals 1492562*
Compsn and methods for the diagnosis and treatment of Herpes simplex virus infection
Corixa Corp 1492563*
Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
Universite Libre de Bruxelles 1492564*
Methods and pharmaceutical compsns for dopaminergic modulation of t-cell adhesion and activity
Levite, Mia 1492565*
Binding agents and their use in targeting tunour cells
AltaRex Medical Corporation 1492566*
Formations and methods of using nitric oxide mimetics in cancer treatment
Cellegy Pharmaceuticals 1492567*
Cancer treatment method comprising administration of an ERB-family inhibitor and a RAF and/or RAS inhibitor
SmithKline Beecham 1492568*
Aqueous dispersible steryl ester compsns
Cargill 1492569*
Method of diagnosis and treatment of breast lesions
Cytyc Corp 1492570*
Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
Janssen Pharmaceutica 1492571*
